Neuphoria Therapeutics Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NEUP and other ETFs, options, and stocks.About NEUP
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.
CEOSpyridon Papapetropoulos
CEOSpyridon Papapetropoulos
Employees24
Employees24
HeadquartersBurlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded1996
Founded1996
Employees24
Employees24
NEUP Key Statistics
Market cap12.75M
Market cap12.75M
Price-Earnings ratio-107.79
Price-Earnings ratio-107.79
Dividend yield—
Dividend yield—
Average volume23.61K
Average volume23.61K
High today$6.84
High today$6.84
Low today$5.90
Low today$5.90
Open price$6.10
Open price$6.10
Volume44.83K
Volume44.83K
52 Week high$12.72
52 Week high$12.72
52 Week low$2.12
52 Week low$2.12
People also own
Based on the portfolios of people who own NEUP. This list is generated using Robinhood data, and it’s not a recommendation.